Graves' disease following administration of second dose of SARS-CoV-2 vaccine
- PMID: 34969799
- PMCID: PMC8719118
- DOI: 10.1136/bcr-2021-246432
Graves' disease following administration of second dose of SARS-CoV-2 vaccine
Abstract
The SARS-CoV-2 vaccines have had an overwhelming success in curbing the COVID-19 global pandemic, accounting for countless lives saved. Adverse reactions are inevitable, given the vast scale of vaccination required to mitigate future surges of COVID-19. Hyperthyroid disorders have been reported as potential adverse reactions to SARS-CoV-2 vaccines in two patients with Graves' disease and a group of adults with subacute thyroiditis occurring in young women healthcare workers. We report a case of clinical Graves' disease in a woman with a previously stable multinodular goitre that occurred 14 days following her second dose of Pfizer-BioNTech SARS-CoV-2 vaccine.
Keywords: COVID-19; thyroid disease; thyrotoxicosis; unwanted effects/adverse reactions.
© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
References
-
- Centers for Disease Control and Prevention . Pfizer-BioNTech COVID-19 vaccine overview and safety. Available: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pf... [Accessed 23 Jun 2021].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical